Lupus-like manifestations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) represent a distinct inflammatory syndrome driven by clonal hematopoietic cells rather than ...

Dr. Shaal Patel, a board certified physician in hematology, oncology, and internal medicine, spoke with Healthline about how myelodysplastic syndromes (MDS) can benefit from supportive therapy, ...

Please provide your email address to receive an email when new articles are posted on . Olutasidenib monotherapy or combination therapy may help certain patients with myelodysplastic syndrome achieve ...

MNV-201, a mitochondrial cell therapy, received FDA fast track designation for myelodysplastic syndrome, highlighting its potential to address mitochondrial dysfunction in this serious blood disorder.

Luspatercept significantly improved hemoglobin levels in non-transfusion-dependent patients with lower-risk myelodysplastic syndromes, potentially delaying transfusion needs. The study showed a 47.6% ...

In the first-line treatment of higher-risk myelodysplastic syndromes (MDS), the combination of venetoclax with azacitidine fell short of the primary endpoint of a reduction in mortality compared with ...

Findings showed 23.8% in the tamibarotene/azacitidine group achieved CR compared with 18.8% in the placebo/azacitidine group (P =.2084). Syros Pharmaceuticals ...

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

Tobacco smoking is linked to specific genetic mutations in MDS, affecting chromatin modification and RNA splicing pathways. A dose-response relationship exists, with higher smoking intensity ...